COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04540419

Nikolay S. Dodonov, PhD

dodonovns@petrovax.ru

2020-09-07

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

inclusion criteria: presence of signed and dated informed consent of volunteer for participation in this study. men and women at the age of 18-85 years. bodyweight index 18.5-30.0 kg/m2. the negative result of the test, performed by using pcr, for the presence of sars-cov-2 rna at the stage of screening. negative result for anti-sars-cov-2 igm and igg antibodies at the stage of screening. no history of the diagnosis covid-19. absence of close contacts with individuals, suspicious for infection sars-cov-2, or individuals, in whom the diagnosis covid-19 was confirmed in laboratory within the last 14 days. absence of signs of respiratory infection within the last 14 days. negative results of human immunodeficiency virus (hiv), syphilis, hepatitis b and hepatitis c tests. according to historical data and results of screening examination, a volunteer has no diseases and/or conditions, which in view of investigator, may influence the safety of volunteer participation and evaluation of study results. volunteer consent for using safe contraceptive methods through all the study.

positive history of allergy, drug intolerance, including increased sensibility to any of components of the test drug product, as well as the history of serious adverse events in the administration of vaccines (such as allergic reactions, respiratory disturbance, angioedema, stomach pain). axillary body temperature ≥37.1 °c at the time of screening/randomization. systolic blood pressure more than 139 mm hg or less than 100 mm hg and/or diastolic blood pressure more than 90 mm hg or less than 60 mm hg. clinical significant abnormal laboratory and/or instrumental parameters at screening examination. acute infectious diseases less than 4 weeks ahead of conduction of screening procedures. acute and acute course of chronic diseases of git, liver, kidneys, cardiovascular, respiratory, nervous and endocrine systems. history of blood and hematopoietic organ diseases. history of diabetes mellitus. history of epilepsy, epileptic syndrome, seizures. history of congenital and acquired immunodeficiency, hiv-infection, lymphoma, leukaemia, systemic lupus erythematosus, juvenile rheumatoid arthritis or other autoimmune diseases. history malignancies. using immunotropic preparations (immunomodulators, immunostimulators, immunodepressants), antiallergic, cytotoxic preparations for more than 10 sequential days within the last 3 months (except for inhalant and local using glucocorticoids [gcs] or using specified preparations less than 4 weeks ahead of the screening. using immunoglobulin preparations or blood transfusion less than 3 months ahead of the screening. using antipyretics (including non-steroidal anti-inflammatory agents and anilides) within 24 hours ahead of randomization. blood donation or loss (≥450 ml of blood or plasma) less than 3 months ahead of the screening. vaccination within 6 mon. ahead of screening or reluctance to refuse from the administration of any other vaccine during the study. anamnestic data/data on alcoholism, narcomania, drug abuse, mental illnesses. major surgery planned within the nearest 6 months or underwent within the last 6 months ahead of the screening. carrying out of body piercing procedures, an appendix of tattoo less than 1 month ahead of conduction of screening procedures and through all the study. pregnancy or breast-feeding period. participation in another clinical study within 3 months ahead of the screening. psychic, physical and other reasons, not allowing a volunteer to adhere to conditions and procedures of study protocol. volunteers, who are clinical site staff. other reasons, not allowing the volunteer to take part in this study in view of the study physician.

2

NPO Petrovax

18

85

Russia

Healthy volunteers

N/A

500

Superiority of the vaccine Ad5-nCoV to placebo by the level of seroconversion

None

Phase 3

[{"arm_notes": "1", "treatment_id": 26, "treatment_name": "Ad5-ncov", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]